Loading...
01/11 11:29
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Despite a strong revenue increase and reduced losses, concerns like logistical challenges, unclear FDA approval timelines, and lack of immediate impact from new product versions temper enthusiasm. The financial performance shows improvement, but the absence of a share repurchase program and management's vague responses during the Q&A add uncertainty. Thus, a neutral stock price movement is expected over the next two weeks.
Revenue $3.7 million (220% increase) compared to $1.2 million for the fiscal year ended March 31, 2024. Growth driven by U.S. sales, primarily from hospitals signed in the latter half of the year.
Gross Profit Loss $1.7 million loss compared to $1.3 million loss for fiscal year 2024. The increase in loss attributed to higher cost of revenue.
Cost of Revenue $5.4 million compared to $2.5 million for fiscal year 2024. Increase due to depreciation of LungFit devices and one-time upgrade costs.
Research and Development Expenses $16.9 million compared with $24.4 million for fiscal year 2024 (decrease of $7.5 million). Decrease attributed to lower salaries, stock-based compensation, and clinical study expenses.
SG&A Expenses $26 million compared to $37.3 million for fiscal year 2024 (decrease of $11.3 million). Decrease primarily due to reduction in salaries and stock-based compensation.
Other Expense $3.9 million compared to $1.3 million a year ago (increase of $2.6 million). Increase mainly due to a noncash loss from the retirement of Avenue Capital debt.
Net Loss $46.6 million or a loss of $0.69 per share compared to $60.2 million or a loss of $1.82 per share for fiscal year 2024. Improvement in net loss attributed to cost reduction efforts.
Net Cash Burn $44.1 million, more than 28% lower than the previous year. Reduction attributed to fixed cost reduction efforts in R&D and supply chain.
Cash, Cash Equivalents and Marketable Securities $6.9 million as of March 31, 2025. This does not include $1 million payment from Getz Healthcare and $2 million investment received after March 31, 2025.
LungFit PH II: Submitted a PMA supplement to FDA for the next-generation system, which is smaller, lighter, and designed for air and ground transportation, with improvements based on customer feedback.
LungFit PH: Continued growth in U.S. sales, with significant revenue increase and new hospital contracts.
NeuroNOS BA-102: Received Orphan Drug Designation from the FDA for treatment of Phelan-McDermid syndrome.
International Expansion: Secured distribution agreements in over 2 dozen countries, covering more than 2 billion lives, including India, Italy, and Ukraine.
Vanderbilt University Partnership: Established as a luminary site for LungFit PH to optimize products and enhance hospital-based nitric oxide therapy.
Cost Reduction: Operating expenses reduced from over $17 million to just above $7 million, a 58% reduction over the past 6 quarters.
Revenue Growth: Reported a 220% increase in revenue to $3.7 million for FY 2025, with guidance of $12 million to $16 million for FY 2026.
Board Appointment: Bob Goodman appointed to the Board of Directors, bringing extensive healthcare executive experience.
LungFit GO Program: Continues to progress towards market introduction for lung infection therapy.
Revenue Growth Risks: Despite a reported 220% increase in revenue, the company faces risks related to sustaining this growth, particularly in the competitive nitric oxide market.
Regulatory Approval Risks: The anticipated FDA approval for the next-generation LungFit PH II system is crucial; any delays or rejections could significantly impact market share and revenue.
Supply Chain Challenges: The company has acknowledged challenges in supply chain management, particularly related to the costs of revenue exceeding revenue due to depreciation and upgrade costs of LungFit devices.
Cash Burn and Financial Stability: The company reported a net loss of $46.6 million and a cash burn of $44.1 million, raising concerns about financial sustainability and the ability to support operations into 2026.
International Market Risks: While expanding into international markets, the company faces regulatory and logistical challenges that could hinder growth and market penetration.
Clinical Trial Risks: The initiation of clinical trials for new therapies, such as those for autism and cancer, is under review, which introduces uncertainty regarding timelines and outcomes.
Revenue Growth: Reported a 220% increase in revenue to $3.7 million for the fiscal year ended March 31, 2025, compared to $1.2 million for the same period last year.
Revenue Guidance Q1 FY 2026: On track to report revenue of at least $1.7 million for the quarter ending June 30, 2025, translating to greater than 45% sequential quarterly growth and greater than 145% year-over-year growth.
Revenue Guidance FY 2026: Providing revenue guidance of $12 million to $16 million for the full fiscal year ending March 31, 2026.
International Expansion: Secured key regulatory approvals and signed distribution agreements across more than 2 dozen countries covering over 2 billion lives.
LungFit PH II Development: Submitted a PMA supplement to FDA for the next-generation system, which is expected to significantly impact market share and logistics.
NeuroNOS Developments: Received Orphan Drug Designation for BA-102, with plans to meet with FDA to discuss the path to human studies expected to begin late in calendar 2026.
Cash Position: As of March 31, 2025, the company had cash, cash equivalents, and marketable securities of $6.9 million, expected to support operations into calendar 2026.
Cost Reduction: Operating expenses reduced from over $17 million to just above $7 million in the current quarter, with further reductions anticipated.
Net Loss: Net loss attributed to common stockholders was $46.6 million for the fiscal year ended March 31, 2025.
Share Repurchase Program: None
The earnings call summary indicates strong financial performance with a 128% YoY revenue increase, reduced gross losses, and significant cost reductions. The Q&A section reveals positive sentiment towards the second-gen LungFit PH, expected to drive further growth, despite supply chain challenges. The company's strategic international expansion and new business model also contribute positively. However, the vague management responses and updated guidance suggest some uncertainty, tempering the overall sentiment. Considering these factors, the stock price is likely to experience a positive movement, especially given the significant revenue growth and cost control.
The earnings call presents strong revenue growth, optimistic guidance, international expansion, and reduced expenses. The Q&A section reveals confidence in achieving guidance, despite some uncertainties in hospital contracts and PMA filings. Cash reserves are solid, supporting operations well into 2026. The company's strategic moves, including the Premier agreement and international partnerships, are expected to drive growth. While management's lack of specific details could be a concern, the overall sentiment is positive, with potential for stock price appreciation in the coming weeks.
Despite a strong revenue increase and reduced losses, concerns like logistical challenges, unclear FDA approval timelines, and lack of immediate impact from new product versions temper enthusiasm. The financial performance shows improvement, but the absence of a share repurchase program and management's vague responses during the Q&A add uncertainty. Thus, a neutral stock price movement is expected over the next two weeks.
The earnings call presents a positive outlook with a 175% revenue increase and improved net loss figures. The company's strategic plans, including international expansion and partnerships, are promising. However, uncertainties in regulatory timelines and lack of specific shareholder return plans temper enthusiasm. The Q&A suggests optimism about future growth and expense reductions, despite some unclear management responses. Overall, the positive revenue growth and strategic initiatives outweigh the concerns, suggesting a positive stock price movement in the near term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
